23andMe Regression Gene Sequencing $199 for new services

On Wednesday, 23andMe officially announced its return, again providing direct-to-consumer genetic testing services and has received FDA approval. 23andMe provides revised personalized genomic services, including information on ancestral sources, health, non-medical characteristics (such as freckles, hair curl, lactose intolerance, etc.) and information on the status of the disease. The new service, priced at $199, helps consumers determine whether to carry genetic mutations associated with hereditary diseases, including cystic fibrosis, family black idiots, and sickle cell anemia.

Unlike before, this time 23andMe does not provide consumers with real-time information on disease risk, but instead focuses on the status of consumers carrying 35 disease-causing genes. This seems very interesting to the parents. If you carry a disease caused by sickle cell anemia? What is the status of the spouse? If both couples carry the disease-causing gene, the probability of a child getting sick in the future is 25%. Answering these questions is the service tenet provided by 23andMe.

Two years ago, out of concern for effectiveness, the US FDA called 23andMe's ultra-low-cost personal genetic reporting service for consumers directly. Anne Wojcicki, co-founder and CEO of 23andMe, told The New York Times that the number of customers has been cut in half since the stop on health information services. Wojcicki told The New York Times that 23andMe still hopes to provide customers with genetic information related to health risks, but is uncertain how long it will take FDA approval. Reuters said that 23andMe is still conducting research on drug response prediction.

The story of 23andMe's return is a warning to companies that disrupt the health system, such as THeranos. You can get what you want, even get more than you expected, but it takes a long time and more work behind it.

COVID-19 Coronavirus Rapid Test Kit

Anesthesia Medical Co., Ltd. , https://www.honestymed.com